Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, because that oh-so-familiar routine of meetings, deadlines, presentations, and the like has, of course, returned. What can you do? The world keeps spinning, even during the tranquil summertime. So time to get cracking as we brew another cup of stimulation — chocolate cherry decadence is our choice today — and forage for interesting items. On that note, here are some tidbits. Have a wonderful day and do keep in touch. …

GlaxoSmithKline (GSK) is set to hire Jonathan Symonds, a former finance director at AstraZeneca (AZN) and Novartis (NVS), as its new chairman to oversee a breakup of the company, The Financial Times reports. The appointment will end a six-month search for a replacement for Philip Hampton, who is currently deputy group chairman of HSBC and has been non-executive chairman at Glaxo since 2015. The move comes as Glaxo and Pfizer (PFE) plan to form a consumer health joint venture.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy